RenovoRx Inc. (RNXT)
RenovoRx Inc. (RNXT) Stock Price, Analysis & Data
| Bid | 0.81 |
| Market Cap | 51.86M |
| Revenue (ttm) | 1.49M |
| Net Income (ttm) | -12.27M |
| Beta | 0.99 |
| EPS (ttm) | -0.33 |
| PE Ratio (ttm) | n/a |
| Forward PE | -7.67 |
| P/B (ttm) | 4.60 |
| P/S (ttm) | 34.83 |
| Earnings Date | Aug 14, 2025 |
| Ask | 1.44 |
| Volume | 268,265 |
| Avg. Volume (20D) | 281,893 |
| Open | 1.14 |
| Previous Close | 1.15 |
| Day's Range | 1.12 - 1.16 |
| 52-Week Range | 0.70 - 1.45 |
| Analyst | Strong Buy |
| Price Target | 5.56 (383.48%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, Calif...
Financial Performance
In 2025, RenovoRx's revenue was 1.12M, an increase of 2,511.63% compared to the previous year's 43K. Earnings were -11.17M, an increase of 26.71%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for RNXT stock is "Strong Buy". The 12-month stock price forecast is 5.56, which is upside of 383.48% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
